钠-葡萄糖共转运蛋白2抑制剂诱发2型糖尿病酮症酸中毒的研究进展  

Research progress on T2DM ketoacidosis Induced by sodium-glucose cotransporter 2 inhibitors

作　　者：赵鸿鼎 尤伟艳[2] ZhaoHongding;You Weiyan(School of Medicine,Shihezi University;First Department of Critical Care Medicine,The First Affiliated Hospital of Shihezi University,Shihezi,China.)

机构地区：[1]石河子大学医学院 [2]石河子大学第一附属医院重症医学一科

出　　处：《实用休克杂志(中英文)》2024年第6期360-364,共5页Journal of Practical Shock

摘　　要：钠-葡萄糖共转运蛋白2抑制剂是一种新型2型糖尿病(T2DM)治疗药物,在控制2型糖尿病患者血糖、降低体重、保护心脑血管和肾脏功能方面均具有显著疗效。但钠-葡萄糖共转运蛋白2抑制剂也可能诱发患者酮症酸中毒,该问题严重影响了其临床使用,但相关的病理生理学机制尚不清楚。如何使2型糖尿病患者通过钠-葡萄糖共转运蛋白2抑制剂治疗收益的同时,更大可能避免发生酮症酸中毒,是基础医学与临床研究的重点。本文根据最新文献报道,总结了钠-葡萄糖共转运蛋白2抑制剂诱发酮症酸中毒的相关机制,旨在为临床用药提供参考。Sodium-glucose co-transporter 2inhibitors(SGLT2i)are a new type of drugs for T2DM,which have significant effects in controlling blood sugar,reducing body weight,and protecting cardiovascular and cerebrovascular functions and renal functions in patients with T2DM.However,SGLT2icauses T2DM ketoacidosis(DKA),which.severely limites the clinical use of SGLT2i,but the mechanisms are still unclear.The central question that both basic and clinical researchers are addressing is how to ensure that T2DM patients benefit from SGLT2itreatment and avoid DKA more likely.Therefore,according to the latest literature and clinical research,this study reviews the research progress on the mechanism of DKA induced by SGLT2i,aiming at providing reference for clinical medication.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 2型糖尿病 酮症酸中毒 

分 类 号：R587.2[医药卫生—内分泌]